An­tipsy­chot­ic from Lund­beck, Ot­su­ka flops again in PhI­II tri­als — this time in bipo­lar pa­tients

New Lund­beck CEO Deb­o­rah Dun­sire has more bad news to con­tend with, five months in­to her ap­point­ment. The Dan­ish drug­mak­er — which is bat­tling with gener­ics …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER